A noncontrolled trial of anti-TNF-α chimeric monoclonal antibody (infliximab, Remicade(®)) in exudative age-related macular degeneration

P Martin van Hagen; G Seerp Baarsma; Christel E van Bilsen; Robert W Kuijpers; Jan A van Laar; Marianne van der Ent; Paul L van Daele; Nico J Veeger; Johannes R Vingerling; Tom O Missotten

doi:10.1111/aos.12471

A noncontrolled trial of anti-TNF-α chimeric monoclonal antibody (infliximab, Remicade(®)) in exudative age-related macular degeneration

P Martin van Hagen, G Seerp Baarsma, Christel E van Bilsen, Robert W Kuijpers, Jan A van Laar, Marianne van der Ent, Paul L van Daele, Nico J Veeger, Johannes R Vingerling, Tom O Missotten

Medical retina and Uveitis

Research output: Contribution to journal › Letter › peer-review

Original language	English
Pages (from-to)	e691-2
Journal	Acta Ophthalmologica
Volume	92
Issue number	8
DOIs	https://doi.org/10.1111/aos.12471
Publication status	Published - Dec 2014

Keywords

Administration, Topical
Aged
Anti-Inflammatory Agents, Non-Steroidal/adverse effects
Antibodies, Monoclonal/adverse effects
Contrast Sensitivity/drug effects
Exudates and Transudates
Humans
Infliximab
Ophthalmic Solutions
Tumor Necrosis Factor-alpha
Visual Acuity/drug effects
Wet Macular Degeneration/drug therapy

Access to Document

10.1111/aos.12471

Cite this

van Hagen, P. M., Baarsma, G. S., van Bilsen, C. E., Kuijpers, R. W., van Laar, J. A., van der Ent, M., van Daele, P. L., Veeger, N. J., Vingerling, J. R., & Missotten, T. O. (2014). A noncontrolled trial of anti-TNF-α chimeric monoclonal antibody (infliximab, Remicade(®)) in exudative age-related macular degeneration. Acta Ophthalmologica, 92(8), e691-2. https://doi.org/10.1111/aos.12471

@article{f4f6b56fd62045ac9136b812e5601dd4,

title = "A noncontrolled trial of anti-TNF-α chimeric monoclonal antibody (infliximab, Remicade({\textregistered})) in exudative age-related macular degeneration",

keywords = "Administration, Topical, Aged, Anti-Inflammatory Agents, Non-Steroidal/adverse effects, Antibodies, Monoclonal/adverse effects, Contrast Sensitivity/drug effects, Exudates and Transudates, Humans, Infliximab, Ophthalmic Solutions, Tumor Necrosis Factor-alpha, Visual Acuity/drug effects, Wet Macular Degeneration/drug therapy",

author = "{van Hagen}, {P Martin} and Baarsma, {G Seerp} and {van Bilsen}, {Christel E} and Kuijpers, {Robert W} and {van Laar}, {Jan A} and {van der Ent}, Marianne and {van Daele}, {Paul L} and Veeger, {Nico J} and Vingerling, {Johannes R} and Missotten, {Tom O}",

year = "2014",

month = dec,

doi = "10.1111/aos.12471",

language = "English",

volume = "92",

pages = "e691--2",

number = "8",

}

van Hagen, PM, Baarsma, GS, van Bilsen, CE, Kuijpers, RW, van Laar, JA, van der Ent, M, van Daele, PL, Veeger, NJ, Vingerling, JR & Missotten, TO 2014, 'A noncontrolled trial of anti-TNF-α chimeric monoclonal antibody (infliximab, Remicade(®)) in exudative age-related macular degeneration', Acta Ophthalmologica, vol. 92, no. 8, pp. e691-2. https://doi.org/10.1111/aos.12471

TY - JOUR

T1 - A noncontrolled trial of anti-TNF-α chimeric monoclonal antibody (infliximab, Remicade(®)) in exudative age-related macular degeneration

AU - van Hagen, P Martin

AU - Baarsma, G Seerp

AU - van Bilsen, Christel E

AU - Kuijpers, Robert W

AU - van Laar, Jan A

AU - van der Ent, Marianne

AU - van Daele, Paul L

AU - Veeger, Nico J

AU - Vingerling, Johannes R

AU - Missotten, Tom O

PY - 2014/12

Y1 - 2014/12

KW - Administration, Topical

KW - Aged

KW - Anti-Inflammatory Agents, Non-Steroidal/adverse effects

KW - Antibodies, Monoclonal/adverse effects

KW - Contrast Sensitivity/drug effects

KW - Exudates and Transudates

KW - Humans

KW - Infliximab

KW - Ophthalmic Solutions

KW - Tumor Necrosis Factor-alpha

KW - Visual Acuity/drug effects

KW - Wet Macular Degeneration/drug therapy

U2 - 10.1111/aos.12471

DO - 10.1111/aos.12471

M3 - Letter

C2 - 24953977

SN - 1755-375X

VL - 92

SP - e691-2

JO - Acta Ophthalmologica

JF - Acta Ophthalmologica

IS - 8

ER -